Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Roivant Sciences Ltd(ROIV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ROIV
10/26/2026: ROIV (4-star) is currently NOT-A-BUY. Pass it for now.
Roivant Sciences is a commercial-stage biotechnology firm known for its decentralized 'Vant' model, where individual subsidiaries manage specific clinical-stage assets. The company's strengths lie in its successful commercialization of VTAMA and its demonstrated ability to monetize drug development programs through high-value divestitures. Its primary growth story revolves around expanding VTAMA's market reach and achieving positive clinical readouts for its pipeline, notably in the autoimmune sector. However, investors must consider the risks of high cash burn, intense competition from established pharmaceutical players, and the binary nature of clinical trials. This stock is best suited for growth-oriented investors who can tolerate significant biotechnology-sector volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is focused on scaling its commercial portfolio and clinical pipeline to generate long-term capital appreciation. |
| Momentum investor | Mixed fit | The stock is subject to significant volatility and reacts sharply to clinical trial results and regulatory updates. |
| Value investor | Weak fit | As a pre-profit or early commercial-stage biotech, traditional value metrics like P/E ratios are often not applicable. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes reinvesting all available cash into drug discovery and development. |
| Low-risk investor | Weak fit | The inherent risks of biopharmaceutical R&D and market competition create high volatility profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical data readouts and FDA decisions, leading to rapid price swings. |
| Valuation risk | Medium / high | Valuations are highly dependent on speculative future cash flows from drugs currently in development. |
| Competition risk (immunology and dermatology) | High | The company operates in crowded markets where larger competitors have established market shares. |
| Business quality | Medium | While the platform model is unique, its long-term consistency depends on continuous success in drug discovery and development. |
| Dividend income | Low / none | Investors should not expect income, as the company retains all capital for growth. |
| Execution risk | Medium / high | The company must successfully navigate the complex, multi-year process of bringing multiple drugs to regulatory approval. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 28.35% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/26/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.36B USD | Price to earnings Ratio - | 1Y Target Price 48.91 |
Price to earnings Ratio - | 1Y Target Price 48.91 | ||
Volume (30-day avg) 7.6M shares | Beta 1.1 | 52 Weeks Range 18.32 - 42.50 | Updated Date 10/25/2026 |
52 Weeks Range 18.32 - 42.50 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the sale of approved medications like VTAMA. | The company earns money directly by selling its medicines to patients and healthcare providers. |
| Licensing and Strategic Divestitures | Payments received from selling subsidiary companies or licensing drug assets to larger firms. | Roivant also generates cash by selling or partnering its successful drug programs to larger pharmaceutical companies. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25.14B | Price to Sales(TTM) 3499.41 |
Enterprise Value 25.14B | Price to Sales(TTM) 3499.41 | ||
Enterprise Value to Revenue 3338.23 | Enterprise Value to EBITDA 0.74 | Shares Outstanding 722.32M | Shares Floating 582.20M |
Shares Outstanding 722.32M | Shares Floating 582.20M | ||
Percent Insiders 21.39 | Percent Institutions 78.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.